Finance

Beta
Lists
2395:TYO
Shin Nippon Biomedical Laboratories Ltd
¥1,217.00
-0.25%
(-3.00) 1D
May 29, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 2395...
Open
¥1,225
High
¥1,241
Low
¥1,217
Mkt. cap
50.67B
Avg. vol.
321.51K
Volume
191.90K
Dividend
4.11%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2025
P/E ratio
11.09
52-wk high
¥2,005
52-wk low
¥1,141
EPS
¥110
Shares outstanding
41.63M
No. of employees
2K
Open
¥1,225
High
¥1,241
Low
¥1,217
Mkt. cap
50.67B
Avg. vol.
321.51K
Volume
191.90K
Dividend
4.11%
Quarterly dividend
¥12
Ex-dividend date
Sep 29, 2025
P/E ratio
11.09
52-wk high
¥2,005
52-wk low
¥1,141
EPS
¥110
Shares outstanding
41.63M
No. of employees
2K
News stories
From sources across the web
About Shin Nippon Biomedical Laboratories Ltd
CEO-
Employees1.52K
Founded1957
Headquarters-
SectorHealth care
Websitesnbl.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.48B
8.29B
6.43B
11.33B
Cost of goods sold
3.41B
4.68B
2.20B
8.00B
Cost of revenue
3.41B
4.68B
2.20B
8.00B
Research and development expenses
-
-
-
2.40B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.41B
3.22B
3.25B
-1.15B
Operating expense
3.41B
3.22B
3.25B
1.70B
Total operating expenses
6.82B
7.90B
5.45B
9.70B
Operating income
-340.94M
389.94M
978.59M
1.63B
Other non operating income
60.44M
54.56M
81.03M
971.39M
EBT including unusual items
333.50M
990.50M
1.43B
3.50B
EBT excluding unusual items
515.75M
1.11B
1.49B
3.58B
Income tax expense
77.00M
209.00M
229.77M
1.20B
Effective tax rate
23.09%
21.10%
16.11%
34.24%
Other operating expenses
-
-
-
-
Net income
260.42M
800.58M
1.21B
2.30B
Net profit margin
4.02%
9.66%
18.82%
20.27%
Earnings per share
-
-
-
-
Interest and investment income
7.68M
88.32M
14.12M
129.02M
Interest expense
-57.82M
-68.18M
-78.15M
-88.61M
Net interest expenses
-50.13M
20.13M
-64.03M
40.40M
Depreciation and amortization charges
-
-
-
411.94M
EBITDA
311.84M
1.17B
1.63B
2.48B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more